BACKGROUND: Survival data that are applicable to the current population of adults with @entity299 ( @entity299 ) are not available. OBJECTIVES: Using an alternative survival analysis with age as the primary time scale, we assessed the contemporary survival of adult @entity1 with @entity299 . METHODS: Survival was assessed using prospective data of the national registry of adult @entity1 with @entity299 of the Netherlands. Survival was stratified by severity and lesion, and compared with a standardised general population. RESULTS: Mean age at inclusion was 37   years, and 49% of the study population was male. During a cumulative prospective follow-up of 90   270 @entity1 -years in 14   327 @entity1 , 535 @entity204 occurred. Median survival was 53.4 (95% CI 49.9 to 60.7), 75.4 (95% CI 72.9 to 79.1) and 84.1 (95% CI 81.9 to 87.0) years for @entity1 with severe, moderate and mild lesions, respectively. Survival of most @entity1 with mild lesions did not differ from the general population, while, as expected, survival of @entity1 with severe and moderate lesions was substantially lower (<0.001). CONCLUSIONS: The present study gives insight in the contemporary survival of adults with @entity299 . This may aid @entity1 counselling, timing of interventions and future research.

Contemporary survival of adults with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity299 :: ('MESH:D006331', 'Disease') :: ['CHD', 'congenital heart disease']
@entity299 :: (MESH:D006331,Disease) :: ['congenital heart disease']
